#phase 3 trial

4 stories

#biotech #cash burn #nasdaq #business #cash runway #clinical pipeline #drug candidate #fda approval #glp-1/gip #going concern #igg4-related disease #inventiva

Pyxis Oncology Stock Bullish
Pyxis Oncology's MICVO drug shows promise for cancer treatment.
Seekingalpha · 1m
Inventiva H1 Results: Cash Runway and NATiV3 at Center
Inventiva's cash runway and NATiV3 trial results drive investor focus after weak H1 earnings.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Viking Therapeutics Data Boosts Hope but Cash Burn Lingers
Viking Therapeutics shows strong VK2735 maintenance data but cash runway remains tight for obesity drug candidate.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Can Zenas BioPharma justify its $108M quarterly burn?
A clinical-stage biotech with $673.9M in cash races toward an FDA decision that will make or break its future.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 2m